INVITED RESEARCH HIGHLIGHT
Year : 2015  |  Volume : 17  |  Issue : 3  |  Page : 437-438

Prostate cancer screening: and yet it moves!


1 Department of Urology, Cantonal Hospital Aarau, Switzerland; Department of Urology, Academic Hospital Braunschweig, Germany
2 Department of Urology, Cantonal Hospital Aarau, Switzerland
3 Department of Urology, Academic Hospital Braunschweig, Germany
4 Department of Laboratory Medicine, Cantonal Hospital Aarau, Switzerland

Correspondence Address:
Maciej Kwiatkowski
Department of Urology, Cantonal Hospital Aarau, Switzerland; Department of Urology, Academic Hospital Braunschweig, Germany

Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1008-682X.143310

Rights and Permissions

The debate of prostate cancer (PCa) screening has been shaped over decades. There is a plethora of articles in the literature supporting as well as declining prostate-specific antigen (PSA) screening. Does screening decrease PCa mortality? With the long-term results of the European Randomized Study of Screening for Prostate (ERSPC) the answer is clearly YES. It moves! However, in medicine there are no benefits without any harm and thus, screening has to be performed in targeted and smart way-or in other words-in a risk-adapted fashion when compared with the way it was done in the past. Here, we discuss the main findings of the ERSPC trials and provide insights on how the future screening strategies should be implemented.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2572    
    Printed49    
    Emailed0    
    PDF Downloaded301    
    Comments [Add]    

Recommend this journal